FERRETAB® COMP.

ABOUT BRAND

  • Brand name:

    FERRETAB® COMP.

  • Dosage form:

    Capsules

  • Composition:

    1 capsule contains: 3 ferrous fumarate minipills and 1 folic acid minipill.
    Active pharmaceutical substance: ferrous fumarate – 163,56 mg (solid equivalent to 152,1 mg, equivalent to 50 mg of ferrum), folic acid – 0,54 mg (solid equivalent to 0,5 mg).
    Excipients: ferrous fumarate minipills: lactose monohydrate – 3,42 mg, colloidal silicon dioxide – 0,6 mg, magnesium – 0,6 mg, methyl methacrylate and ethyl acrylate copolymer [2 : 1] – 4,66 mg, folic acid minipill: lactose monohydrate – 24,21 mg, microcrystalline cellulose – 24,25 mg, colloidal silicon dioxide – 0,5 mg, magnesium – 0,5 mg.
    Capsule body: gelatin – 36,4804 mg, azorubine dye – 0,0742 mg, quinoline yellow dye – 0,1484 mg, titanium dioxide – 0,4960 mg.
    Capsule cap: gelatin – 24,3203 mg, azorubine dye – 0,0498 mg, quinoline yellow dye – 0,0996 mg, titanium dioxide – 0,3303 mg.

  • ФЕРРЕТАБ® КОМП.
  • ФЕРРЕТАБ® КОМП.

Combined medicines of iron organic salt and folic acid in capsules of prolonged action for the iron deficiency treatment and prevention, especially during pregnancy.

 

Description

Size 2 solid gelatin capsules, red body and cap. Capsule contains 3 reddish-brown round flat minipills (ferrous fumarate) and 1 yellow round flat minipill (folic acid). Inclusions are allowed on tablets.

 

Indications

Treatment of latent iron deficiency and iron deficiency anemia, combined with folic acid deficiency, including during pregnancy.

 

Counterindications

— Hypersensitivity to the active ingredients or to any of the excipients

— Diseases accompanied by accumulation of iron in the body: hemochromatosis, hemosiderosis, chronic hemolysis

— Iron absorption disorders: sideroachrestic anemia, thalassemia, lead anemia

— Hemoglobinopathies, hemolytic anemia, aplastic anemia, pernicious anemia, anemia not caused by iron and folic acid deficiency

— Gastrointestinal disorders

— Patients with rare hereditary problems of galactose intolerance, lactase deficiency or malabsorption

— Children and adolescents under 18 years of age

Events 25 February
    We use cookies

    By using this website, you consent to the collection and processing of your personal data, including through the use of third-party services, cookies and web analytics, on the terms and conditions set out in the Policy on personal data processing for websites and hotlinePersonal Data Processing Policy. You also accept the terms and conditions of our Пользовательского соглашенияUser Agreement.

    en_USEnglish